Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsCPRX +0.02%70 Shiller PE Ratio is 53.37 as of Sep. 02, 2026, which is 39% below its 10-year median of 88.04. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.01 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 171 Biotechnology companies, Catalyst Pharmaceuticals ranks worse than 67.25% on this metric.
The historical rank and industry rank for Catalyst Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:
CPRX'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 41.85 Med: 88.04 Max: 950.5
Current: 53.75
During the past years, Catalyst Pharmaceuticals's highest Shiller PE Ratio was 950.50. The lowest was 41.85. And the median was 88.04.
CPRX's Shiller PE Ratio is ranked worse than 67.25% of 171
companies
in the Biotechnology industry
Industry Median: 32.7
vs CPRX: 53.75
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.500. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.59 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Catalyst Pharmaceuticals (NAS:CPRX) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Catalyst Pharmaceuticals Shiller PE Ratio Related Terms
Catalyst Pharmaceuticals Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPRX vs PBLS, ELVN, RLAY: Shiller PE Ratio Comparison
For the Biotechnology subindustry, Catalyst Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's Shiller PE Ratio falls into.
Catalyst Pharmaceuticals Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Catalyst Pharmaceuticals (CPRX) has a Shiller PE Ratio of 53.37 as of Sep. 02, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Catalyst Pharmaceuticals and its competitors. This is 39% below median its historical median of 88.04. Over the past decade, Catalyst Pharmaceuticals' Shiller PE Ratio has ranged from 41.85 to 950.50. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #115 out of 171 companies in the Biotechnology industry, placing it in the top 67.3%.
Is Catalyst Pharmaceuticals' Shiller PE Ratio too high?
Catalyst Pharmaceuticals' current Shiller PE Ratio of 53.37 is 39% below median its 10-year median of 88.04. Over the past 10 years, this metric has ranged from a low of 41.85 to a high of 950.50. The Biotechnology industry median Shiller PE Ratio is 32.70. Catalyst Pharmaceuticals' value of 53.37 is 63.2% above this industry median. Based on the distribution chart, Catalyst Pharmaceuticals ranks #115 out of 171 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Shiller PE Ratio compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #115 out of 171 companies for Shiller PE Ratio. This places Catalyst Pharmaceuticals in the lower half of its industry. The industry median Shiller PE Ratio is 32.70. Catalyst Pharmaceuticals' value of 53.37 is 63.2% above this benchmark. Historically, Catalyst Pharmaceuticals' own Shiller PE Ratio has ranged from 41.85 to 950.50 over the past decade. While the company's 10-year median is 88.04 vs. the industry median of 32.70, Catalyst Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Biotechnology company?
The median Shiller PE Ratio among Biotechnology companies is 32.70, based on 171 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catalyst Pharmaceuticals's current Shiller PE Ratio of 53.37 is 63.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Catalyst Pharmaceuticals and its competitors. For the Biotechnology industry, the median Shiller PE Ratio is 32.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catalyst Pharmaceuticals's current Shiller PE Ratio is 53.37, which is 39% below median its own 10-year median of 88.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.01, compared to a current price of $31.49 — trading 25.9% above its estimated fair value. The current Shiller PE Ratio is 53.37, which is 39% below median its 10-year median of 88.04 and 63.2% above the Biotechnology industry median of 32.70. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current Shiller PE Ratio is 53.37 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of $31.49 is trading 25.9% above its estimated GF Value™ of $25.01.
GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for CPRX:
Shiller PE Ratio: 53.37 (39% below median its 10-year median of 88.04)
GF Value™: $25.01 vs. price of $31.49 (25.9% above fair value)
Industry Position: 63.2% above the Biotechnology median (#115 of 171)
No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score
Get the complete analysis for CPRX
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPRX has been successfully added to your 
